BRAF status in personalizing treatment approaches for pediatric gliomas

PURPOSE: Alteration of the BRAF/MEK/MAPK pathway is the hallmark of pediatric low-grade gliomas (PLGG) and mTOR activation has been documented in the majority of these tumors. We investigated combinations of MEK1/2, BRAF(V600E) and mTOR inhibitors in gliomas carrying specific genetic alterations of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Olow, Aleksandra, Mueller, Sabine, Yang, Xiaodong, Hashizume, Rintaro, Meyerowitz, Justin, Weiss, William, Resnick, Adam C., Waanders, Angela J., Stalpers, Lukas J. A., Berger, Mitchel S., Gupta, Nalin, James, C. David, Petritsch, Claudia, Haas-Kogan, Daphne A.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5093033/
https://ncbi.nlm.nih.gov/pubmed/27217440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1101
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires